UBS Group AG Raises Position in Zai Lab Limited (NASDAQ:ZLAB)

UBS Group AG lifted its holdings in Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 45.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 219,161 shares of the company’s stock after buying an additional 68,205 shares during the quarter. UBS Group AG owned approximately 0.22% of Zai Lab worth $6,728,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. increased its holdings in Zai Lab by 138.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 45,213 shares of the company’s stock worth $1,939,000 after purchasing an additional 26,250 shares during the period. BlackRock Inc. boosted its position in Zai Lab by 6.3% during the 1st quarter. BlackRock Inc. now owns 3,924,215 shares of the company’s stock valued at $172,587,000 after acquiring an additional 231,759 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in Zai Lab by 11.7% during the 1st quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 35,511 shares of the company’s stock valued at $1,562,000 after acquiring an additional 3,711 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Zai Lab during the 1st quarter valued at $210,000. Finally, Aviva PLC boosted its position in Zai Lab by 1.1% during the 1st quarter. Aviva PLC now owns 35,870 shares of the company’s stock valued at $1,578,000 after acquiring an additional 400 shares in the last quarter. 59.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Harald Reinhart sold 11,480 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $40.00, for a total transaction of $459,200.00. Following the transaction, the insider now directly owns 18,958 shares in the company, valued at approximately $758,320. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Zai Lab news, Director William Lis sold 5,434 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $38.31, for a total value of $208,176.54. Following the sale, the director now owns 23,330 shares of the company’s stock, valued at $893,772.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Harald Reinhart sold 11,480 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $40.00, for a total value of $459,200.00. Following the completion of the sale, the insider now directly owns 18,958 shares in the company, valued at approximately $758,320. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,879 shares of company stock worth $990,357. Insiders own 6.26% of the company’s stock.

Zai Lab Trading Down 5.9 %

NASDAQ ZLAB opened at $31.83 on Friday. The stock has a 50-day simple moving average of $34.54 and a two-hundred day simple moving average of $36.07. Zai Lab Limited has a fifty-two week low of $20.98 and a fifty-two week high of $53.95.

Zai Lab (NASDAQ:ZLAB – Get Rating) last announced its quarterly earnings results on Wednesday, March 1st. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.39. Zai Lab had a negative return on equity of 37.58% and a negative net margin of 177.42%. The firm had revenue of $62.60 million during the quarter, compared to analyst estimates of $62.79 million. On average, research analysts anticipate that Zai Lab Limited will post -3.46 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ZLAB. JPMorgan Chase & Co. dropped their target price on Zai Lab from $79.00 to $70.00 and set an “overweight” rating on the stock in a research report on Thursday, March 16th. Citigroup reduced their target price on Zai Lab from $138.00 to $130.00 in a research note on Thursday, May 11th.

Zai Lab Profile

(Get Rating)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.